Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...


News & Press Releases

Here you will find the most recent organizational news from FARA, including information on events, and awareness and advocacy initiatives. To locate an article from a certain date, please use the archives on the right side of your screen.

Ride Ataxia NorCal Press Release

Can't see this document? Click Here

The Outback Steakhouse Pro-Am Teams Up with Ride Ataxia Tampa Bay

Can't see this document? Click Here

Neurology Now - Friedreich's Ataxia

This article just came out in Neurology Now, a publication of the American Academy of Neurologists. This publication is sent to neurologists offices around the country and distributed in waiting rooms and offices. The article focuses on one approach to therapy that FARA has been supporting, HDAC inhibition. The article is not comprehensive, it does not review all of the potential therapies, however it does recognize the promise and progress of FA research, specifically HDAC inhibitors, and highlights the work of Dr. Joel Gottesfeld, a FARA funded researcher.

Can't see this document? Click Here

Classmate's disorder leads to school effort

Alec Gaston usually takes his time between the bells at Perrysburg High School, walking to his locker and chatting with friends in the hallways.

Not yesterday.

The high school junior needed those five minutes to power down the hallways in a wheelchair.

The 16-year-old was one of three students and six staff members who spent the day using wheelchairs to raise awareness about classmate Zac Zies' degenerative neuromuscular disorder called Friedreich's ataxia.

Alec said he was surprised at how physically demanding it was to navigate through the school in a wheelchair. It was tricky to open the doors, to roll around the crowds in the hallway. His arms ached.

"The kids that are in these wheelchairs - I have no idea how they do it every day," Alec said. "My daily routine has just been thrown off. I can't talk to people in the hallways. I'm literally trying to get from A to B."

Read More: Classmate's disorder leads to school effort

Repligen Corporation F3Q10 (Qtr End 12/31/09) Earnings Call Transcript

Thank you and good morning. The purpose of today’s call is to briefly review our financial results for Q3 of our fiscal year 2010, update our financial projections for the year and to update the status of our development programs. Joining me today is Walter Herlihy, our President and CEO.

At the outset, I'd like to state that this discussion will contain certain forward-looking statements which are not guarantees of future performance such as our financial projections and projections for the U.S. sales of Orencia, opportunities for licensing, our intellectual property portfolio and our plans and projections for clinical trials.

These statements are subject to certain factors which may cause Repligen's plans to materially differ or results to materially vary from those expected including market acceptance of our products, unexpected preclinical or clinical results or delays, delays in manufacturing by us or our partners, failure to receive adequate supply of clinical materials from our partners, timing of product orders, delays in or failure of regulatory approval, adverse changes in commercial relationships and a variety of other risks set forth in our filings with the Securities and Exchange Commission including, but not limited to, our Annual Report on Form 10-K. Except in circumstances in which prior disclosure becomes materially misleading in light of subsequent events, we do not intend to update any of these forward-looking statements.

Read More: Repligen Corporation F3Q10 (Qtr End 12/31/09) Earnings Call Transcript

Page 72 of 87


Event D.jpg

News & Press Archives

Site Map     Privacy Policy     Service Terms     Log-in     Contact     Charity Navigator